Melasma is a natural darkening of the skin on the face caused by excessive production of melanin. Melasma can be mild, moderate or severe, depending on how much of the face is discolored and how much darker than normal the skin has become. Melasma may be triggered by normal hormonal changes in women — during pregnancy or when taking birth control pills or hormone replacement therapy.

Tri-Luma® Cream (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) is the only treatment of moderate to severe melasma of the face.

Tri-Luma® Cream:
- Proven safe for intermittent use up to six months within a 12-month period
- No skin atrophy and no increase in severity of side effects versus short-term (8-week) use
- Fluocinolone acetonide is a low-potency, class 6 steroid
- The only melasma therapy that combines three active ingredients — a low potency corticosteroid (fluocinolone acetonide), hydroquinone, and tretinoin — in one stable formulation
- Tri-Luma® Cream is for short-term and intermittent long-term therapy for up to six months of cumulative drug exposure
- Tri-Luma® Cream is the only hydroquinone (4.0%)-based product for melasma approved by the FDA
- Clinically proven to lighten moderate-to-severe melasma in eight weeks³ in a high percentage of test results
- Favorable safety profile and well tolerated by patients³
- For best results Tri-Luma® Cream must be used with measures to avoid sun exposure.

For more information on Tri-Luma®, visit www.TriLuma.com. Tri-Luma® is only available by prescription. For more information on Galderma, visit www.GaldermaUSA.com.

Galderma Laboratories, L.P. • 14501 N. Freeway • Fort Worth, TX 76177

Please see reverse side for more information regarding Tri-Luma®.
Tri-Luma® Cream is contraindicated in individuals with a hypersensitivity, allergy or intolerance to fluocinolone acetonide, hydroquinone or tretinoin. In clinical trials, the most frequently reported side effects were erythema, desquamation, burning, dryness and pruritus.

Mild to moderate redness, peeling, burning, dryness or itching may be experienced. This product contains sulfites that may cause severe allergic reactions including anaphylactic symptoms and life-threatening asthma attacks. Exposure to sunlight, sunlamps or UV light and extreme heat, wind or cold should be avoided. Use of sunscreen with appropriate SPF of 30 or higher is required. Wear protective clothing and change to nonhormonal forms of birth control, if hormonal methods are used.

Tri-Luma® Cream contains hydroquinone, which may produce exogenous ochronosis, a gradual blue-black darkening of the skin, whose occurrence should prompt discontinuation of therapy. Tri-Luma® Cream contains the corticosteroid fluocinolone acetonide. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for corticosteroid insufficiency after withdrawal of treatment.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.